Adicet Bio Q2 FY26 net loss widens to $21.4 million; cash and short-term investments total $118.2 million
ACET•Pipeline updates
- The Phase 1 prula-cel update in lupus nephritis and SLE is now expected in 3Q 2026, with topline results anticipated in 3Q 2026.
- Regulatory filing for ADI-212 in mCRPC is targeted for 3Q 2026, with Phase 1 enrollment expected to begin in 4Q 2026 pending clearance.
Second-quarter financial results
Adicet Bio posted a net loss of $21.4 million, or $1.99 per share, for the second quarter ended June 30, 2026.
- R&D expense totaled $18.5 million.
- G&A expense was $3.9 million.
- Cash, cash equivalents and short-term investments were $118.2 million.
- Funding runway is expected into the second half of 2027.
